Patents by Inventor Robert Radinsky

Robert Radinsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190048423
    Abstract: The present application relates to K-ras mutations, to polynucleotides encoding mutant K-ras polypeptides, and to methods of identifying K-ras mutations. The present application also relates to methods of diagnosing cancer; and methods and kits for predicting the usefulness of anti-EGFr specific binding agents in the treatment of tumors.
    Type: Application
    Filed: June 21, 2018
    Publication date: February 14, 2019
    Applicant: AMGEN INC.
    Inventors: Daniel J Freeman, Todd Juan, Robert Radinsky
  • Patent number: 10030270
    Abstract: The present application relates to K-ras mutations, to polynucleotides encoding mutant K-ras polypeptides, and to methods of identifying K-ras mutations. The present application also relates to methods of diagnosing cancer; and methods and kits for predicting the usefulness of anti-EGFr specific binding agents in the treatment of tumors.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: July 24, 2018
    Assignee: AMGEN, INC
    Inventors: Daniel Freeman, Todd Juan, Robert Radinsky
  • Patent number: 9988462
    Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
    Type: Grant
    Filed: January 18, 2016
    Date of Patent: June 5, 2018
    Inventors: Thore Hettmann, Daniel J. Freeman, Robert Radinsky, Mike Rothe
  • Publication number: 20180134805
    Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
    Type: Application
    Filed: October 27, 2017
    Publication date: May 17, 2018
    Applicants: Daiichi Sankyo Europe Gmbh, Amgen Inc.
    Inventors: THORE HETTMANN, DANIEL J. FREEMAN, ROBERT RADINSKY
  • Patent number: 9803025
    Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: October 31, 2017
    Assignees: AMGEN, INC., Daiichi Sankyo Europe GmbH
    Inventors: Thore Hettmann, Daniel J. Freeman, Robert Radinsky
  • Publication number: 20160222126
    Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
    Type: Application
    Filed: January 18, 2016
    Publication date: August 4, 2016
    Applicants: U3 PHARMA GMBH, AMGEN, INC.
    Inventors: Thore Hettmann, Daniel J. Freeman, Robert Radinsky, Mike Rothe
  • Patent number: 9101760
    Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: August 11, 2015
    Assignees: U3 Pharma GmbH, Amgen, Inc.
    Inventors: Thore Hettmann, Daniel J. Freeman, Robert Radinsky
  • Patent number: 9097729
    Abstract: The present application relates to methods of selecting EGFr binding agents. In certain embodiments, such EGFr binding agents bind to at least a portion of a panitumumab epitope on an EGFr. In certain embodiments, such EGFr binding agents do not bind to a panitumumab epitope on an EGFr.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: August 4, 2015
    Assignee: AMGEN INC.
    Inventors: Daniel J. Freeman, Jilin Sun, Kenneth H. Jung, Gary S. Elliott, Robert Radinsky
  • Publication number: 20150051091
    Abstract: The present application relates to methods of selecting EGFr binding agents. In certain embodiments, such EGFr binding agents bind to at least a portion of a panitumumab epitope on an EGFr. In certain embodiments, such EGFr binding agents do not bind to a panitumumab epitope on an EGFr.
    Type: Application
    Filed: July 26, 2011
    Publication date: February 19, 2015
    Inventors: Daniel J. Freeman, Jilin Sun, Kenneth H. Jung, Gary S. Elliott, Robert Radinsky
  • Patent number: 8771695
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: July 8, 2014
    Assignees: U3 Pharma GmbH, Amgen, Inc.
    Inventors: Mike Rothe, Martin Treder, Susanne Hartmann, Daniel J. Freeman, Robert Radinsky, Eric Borges
  • Patent number: 8546107
    Abstract: Mutations of the epidermal growth factor receptor (EGFr), of phosphatidylinositol 3?-kinase (“PI3K”), and of B-Raf are described. Methods of treating tumors containing mutated EGFr with human monoclonal antibodies against EGFr are described. Methods and kits for ascertaining the presence of one or more mutant EGFr, mutant PI3K, and/or mutant B-Raf in a sample and for treating disorders or conditions related to the presence of mutant EGFr, mutant PI3K, and/or mutant B-Raf are also described. Methods of treating tumors containing mutant EGFr, mutant PI3K, and/or mutant B-Raf are also described.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: October 1, 2013
    Assignee: Amgen Inc.
    Inventors: Daniel J Freeman, Todd Juan, Robert Radinsky
  • Publication number: 20120328620
    Abstract: Mutations of the epidermal growth factor receptor (EGFr), of phosphatidylinositol 3?-kinase (“PI3K”), and of B-Raf are described. Methods of treating tumors containing mutated EGFr with human monoclonal antibodies against EGFr are described. Methods and kits for ascertaining the presence of one or more mutant EGFr, mutant PI3K, and/or mutant B-Raf in a sample and for treating disorders or conditions related to the presence of mutant EGFr, mutant PI3K, and/or mutant B-Raf are also described. Methods of treating tumors containing mutant EGFr, mutant PI3K, and/or mutant B-Raf are also described.
    Type: Application
    Filed: July 15, 2011
    Publication date: December 27, 2012
    Applicant: AMGEN INC
    Inventors: Daniel J. FREEMAN, Todd JUAN, Robert RADINSKY
  • Publication number: 20120264129
    Abstract: The present application relates to K-ras mutations, to polynucleotides encoding mutant K-ras polypeptides, and to methods of identifying K-ras mutations. The present application also relates to methods of diagnosing cancer; and methods and kits for predicting the usefulness of anti-EGFr specific binding agents in the treatment of tumors.
    Type: Application
    Filed: June 14, 2012
    Publication date: October 18, 2012
    Inventors: Daniel Freeman, Todd Juan, Robert Radinsky
  • Publication number: 20120156130
    Abstract: Described herein are materials and methods for using a HER3 binding agent for prostate treatment. The HER3 binding agent can be, for example, an antibody, and can be used to treat conditions such as benign prostate hyperplasia (BPH) and prostate cancer.
    Type: Application
    Filed: August 8, 2011
    Publication date: June 21, 2012
    Inventors: Thore HETTMANN, Daniel J. Freeman, Robert Radinsky, Darrin M. Beaupre
  • Publication number: 20120058122
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Application
    Filed: April 15, 2010
    Publication date: March 8, 2012
    Inventors: Mike Rothe, Martin Treder, Susanne Hartmann, Daniel J. Freeman, Robert Radinsky, Eric Borges, Larry L. Green
  • Publication number: 20110229406
    Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
    Type: Application
    Filed: November 12, 2010
    Publication date: September 22, 2011
    Applicants: U3 PHARMA GMBH, AMGEN
    Inventors: THORE HETTMANN, DANIEL J. FREEMAN, ROBERT RADINSKY
  • Patent number: 7985559
    Abstract: The present application relates to methods of selecting EGFr binding agents. In certain embodiments, such EGFr binding agents bind to at least a portion of a panitumumab epitope on an EGFr. In certain embodiments, such EGFr binding agents do not bind to a panitumumab epitope on an EGFr.
    Type: Grant
    Filed: October 17, 2008
    Date of Patent: July 26, 2011
    Assignee: AMGEN Inc.
    Inventors: Daniel J. Freeman, Jilin Sun, Kenneth H. Jung, Gary S. Elliott, Robert Radinsky
  • Patent number: 7981605
    Abstract: Mutations of the epidermal growth factor receptor (EGFr), of phosphatidylinositol 3?-kinase (“Pl3K”), and of B-Raf are described. Methods of treating tumors containing mutated EGFr with human monoclonal antibodies against EGFr are described. Methods and kits for ascertaining the presence of one or more mutant EGFr, mutant Pl3K, and/or mutant B-Raf in a sample and for treating disorders or conditions related to the presence of mutant EGFr, mutant Pl3K, and/or mutant B-Raf are also described. Methods of treating tumors containing mutant EGFr, mutant Pl3K, and/or mutant B-Raf are also described.
    Type: Grant
    Filed: February 23, 2006
    Date of Patent: July 19, 2011
    Assignee: Amgen Inc.
    Inventors: Daniel J. Freeman, Todd Juan, Robert Radinsky
  • Publication number: 20100183631
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Application
    Filed: February 4, 2009
    Publication date: July 22, 2010
    Inventors: Mike Rothe, Martin Treder, Susanne Hartmann, Daniel J. Freeman, Robert Radinsky
  • Publication number: 20090123937
    Abstract: The present application relates to methods of selecting EGFr binding agents. In certain embodiments, such EGFr binding agents bind to at least a portion of a panitumumab epitope on an EGFr. In certain embodiments, such EGFr binding agents do not bind to a panitumumab epitope on an EGFr.
    Type: Application
    Filed: October 17, 2008
    Publication date: May 14, 2009
    Inventors: Daniel J. Freeman, Jilin Sun, Kenneth H. Jung, Gary E. Elliott, Robert Radinsky